Ardelyx (ARDX)
(Delayed Data from NSDQ)
$7.77 USD
-0.29 (-3.60%)
Updated May 10, 2024 04:00 PM ET
After-Market: $7.78 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Ardelyx (ARDX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.83 | $16.00 | $11.00 | 71.59% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Ardelyx comes to $13.83. The forecasts range from a low of $11.00 to a high of $16.00. The average price target represents an increase of 71.59% from the last closing price of $8.06.
Analyst Price Targets (9 )
Broker Rating
Ardelyx currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, 10 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 9 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/3/2024 | LadenburgThalmann | Matthew L Kaplan | Strong Buy | Strong Buy |
5/3/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
4/17/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
4/5/2024 | SVB Securities | Roanna Ruiz | Not Available | Strong Buy |
2/23/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
1/9/2024 | Raymond James | Steven Seedhouse | Strong Buy | Strong Buy |
9/12/2023 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 10 |
Average Target Price | $13.83 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 99 of 252 |
Current Quarter EPS Est: | -0.11 |